~~<i id='C57C52DE41'><strike id='C57C52DE41'><tt id='C57C52DE41'><pre id='C57C52DE41'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：fashion 2025-09-09 05:35:41 - browse：447

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

focus

leisure time

knowledge

leisure time

hotspot

focus

AdobeLastJanuary,Iwenttofillmyson’sADHDprescriptionandwashandedabagwithanunfamiliardrugnameonit.Nomi

WSS

CVS is willing to dump 10% of its Medicare Advantage members

Copay coupons to count toward deductibles, after Biden court move

HHS suspends federal funding for EcoHealth Alliance

Biotech venture capitalists face new demands from investors

Obesity drug from Roche shows promise in early study

Cherokee Nation medical school graduates its first class

hotspot

comprehensive

focus

Peter Hotez and the public health issue of online harassment

Novo Nordisk testing Wegovy against alcohol

Virginia high school admissions case could be legal follow

HHS suspends federal funding for EcoHealth Alliance

How to save PrEP access — and even expand it

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

After affirmative action ruling, medical educators look to 'holistic review'

How digital therapeutics firms are pivoting after Pear's bankruptcy

After affirmative action ruling, medical educators look to 'holistic review'

Obesity drug from Roche shows promise in early study

leisure time

Think you might have Covid

WuXi Biologics beefs up its lobbying operation

Test for long Covid? Researchers find new clue in blood samples

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

AI generated plenty of interest at JPM but not a lot of trust

Supreme Court to hear if Covid misinformation is protected speech

knowledge

leisure time

hotspot

focus